U.S. Markets open in 54 mins.

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,425.50-21.50 (-0.48%)
As of 1:21PM BST. Market open.
Full screen
Previous Close4,447.00
Bid4,425.00 x 6100
Ask4,426.00 x 13000
Day's Range4,396.50 - 4,435.00
52 Week Range3,996.00 - 5,520.00
Avg. Volume2,141,770
Market Cap56.02B
PE Ratio (TTM)16.57
Earnings DateN/A
Dividend & Yield2.79 (4.92%)
Ex-Dividend Date2017-08-10
1y Target EstN/A
  • Barrons.com3 days ago

    Tesaro: Losing Its Edge?

    The FDA decided yesterday to expand the use of the ovarian cancer drug Lynparza, sold by AstraZeneca (AZN) and Merck (MRK). The two drugs belong to a class known as PARP inhibitors. Approved in 2014, AstraZeneca's Lynparza was the first such drug to make its way through the FDA.

  • Barrons.com3 days ago

    Ovarian Cancer Market Still Up For Grabs

    The Food and Drug Administration approved a broader label for AstraZeneca’s (AZN) breast cancer drug Lynparza to be used in ovarian cancer patients. Morgan Stanley’s Andrew Berens and his team are updating their models following the news, writing that he expects the three major players—AstraZeneca, Clovis Oncology (CLVS), and Tesaro (TSRO)—will likely split the market for second line (2L) treatment.

  • AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion
    Zacks3 days ago

    AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion

    AstraZeneca, plc (AZN) and partner Merck's ovarian cancer drug, Lynparza has received FDA approval for new tablet formulation and a broader U.S. label.